3/24/2011 8:06:53 AM
CLEVELAND & SUNNYVALE, Calif.--(BUSINESS WIRE)--Molecular Devices, Inc. and ChanTest Corporation, leading providers of ion channel and GPCR drug discovery tools and solutions, have signed an agreement for Molecular Devices to distribute ChanTest’s extensive portfolio of ion channel and GPCR cell lines on a non-exclusive basis. As part of the agreement, Molecular Devices, Inc. will sell ChanTest’s ion channel and GPCR cell lines and promote ChanTest’s cell optimization services to its PatchXpress® 7000A, IonWorks® Quattro, IonWorks Barracuda™ and FLIPRTETRA® system customers worldwide. ChanTest has a portfolio of more than 145 ion channel and 110 GPCR cell lines.
comments powered by